Healthcare provider profile · identity verified

Jamil Razzaq, DO

Internal Medicine · SUN CITY WEST, AZ · NPI 1265472443

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	1005	293
Amlodipine Besylate	Amlodipine Besylate	926	269
Levothyroxine Sodium	Levothyroxine Sodium	741	201
Metoprolol Succinate	Metoprolol Succinate	731	207
Losartan Potassium	Losartan Potassium	728	214
Simvastatin	Simvastatin	639	180
Omeprazole	Omeprazole	510	172
Lisinopril	Lisinopril	433	131
Rosuvastatin Calcium	Rosuvastatin Calcium	371	114
Metformin Hcl	Metformin Hcl	295	91
Pantoprazole Sodium	Pantoprazole Sodium	281	94
Tamsulosin Hcl	Tamsulosin Hcl	276	87
Hydrochlorothiazide	Hydrochlorothiazide	203	55
Terazosin Hcl	Terazosin Hcl	187	54
Allopurinol	Allopurinol	181	59
Gabapentin	Gabapentin	176	62
Trazodone Hcl	Trazodone Hcl	176	62
Lovastatin	Lovastatin	166	44
Potassium Chloride	Potassium Chloride	154	54
Metoprolol Tartrate	Metoprolol Tartrate	150	47
Eliquis	Apixaban	148	46
Fluoxetine Hcl	Fluoxetine Hcl	142	44
Alendronate Sodium	Alendronate Sodium	126	39
Furosemide	Furosemide	126	45
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	122	31
Ezetimibe	Ezetimibe	119	38
Carvedilol	Carvedilol	117	37
Clopidogrel	Clopidogrel Bisulfate	108	34
Montelukast Sodium	Montelukast Sodium	108	38
Famotidine	Famotidine	107	38
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	104	32
Glipizide Er	Glipizide	103	31
Pravastatin Sodium	Pravastatin Sodium	99	29
Glimepiride	Glimepiride	97	31
Metformin Hcl Er	Metformin Hcl	87	29
Fluticasone Propionate	Fluticasone Propionate	85	36
Chlorthalidone	Chlorthalidone	83	23
Finasteride	Finasteride	80	25
Synthroid	Levothyroxine Sodium	77	23
Atenolol	Atenolol	75	23
Sertraline Hcl	Sertraline Hcl	74	18
Albuterol Sulfate Hfa	Albuterol Sulfate	70	35
Warfarin Sodium	Warfarin Sodium	69	20
Pioglitazone Hcl	Pioglitazone Hcl	68	19
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	61	22
Xarelto	Rivaroxaban	58	15
Nifedipine Er	Nifedipine	57	19
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	48	15
Venlafaxine Hcl Er	Venlafaxine Hcl	48	15
Benazepril Hcl	Benazepril Hcl	47	13
Citalopram Hbr	Citalopram Hydrobromide	47	15
Escitalopram Oxalate	Escitalopram Oxalate	46	14
Hydralazine Hcl	Hydralazine Hcl	44	15
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	44	12
Ciprofloxacin Hcl	Ciprofloxacin Hcl	42	36
Oxybutynin Chloride Er	Oxybutynin Chloride	42	15
Fenofibrate	Fenofibrate	41	14
Isosorbide Mononitrate Er	Isosorbide Mononitrate	41	12
Spironolactone	Spironolactone	40	18
Duloxetine Hcl	Duloxetine Hcl	38	14
Ipratropium Bromide	Ipratropium Bromide	38	21
Primidone	Primidone	37	11
Diltiazem 24hr Er	Diltiazem Hcl	35	12
Methylprednisolone	Methylprednisolone	35	33
Celecoxib	Celecoxib	32	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	31	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	31	suppressed
Propranolol Hcl	Propranolol Hcl	31	suppressed
Donepezil Hcl	Donepezil Hcl	30	12
Labetalol Hcl	Labetalol Hcl	30	suppressed
Valsartan	Valsartan	30	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	30	suppressed
Amoxicillin	Amoxicillin	28	16
Gemfibrozil	Gemfibrozil	28	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	28	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	27	suppressed
Azithromycin	Azithromycin	25	23
Mirtazapine	Mirtazapine	25	suppressed
Acyclovir	Acyclovir	24	suppressed
Valacyclovir	Valacyclovir Hcl	24	11
Estradiol	Estradiol	23	11
Paroxetine Hcl	Paroxetine Hcl	23	suppressed
Irbesartan	Irbesartan	22	suppressed
Enalapril Maleate	Enalapril Maleate	21	suppressed
Verapamil Er	Verapamil Hcl	21	suppressed
Dutasteride	Dutasteride	20	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	20	suppressed
Bupropion Hcl Sr	Bupropion Hcl	19	suppressed
Digoxin	Digoxin	18	suppressed
Farxiga	Dapagliflozin Propanediol	18	suppressed
Memantine Hcl	Memantine Hcl	18	suppressed
Ozempic	Semaglutide	18	suppressed
Prednisone	Prednisone	18	16
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	17	suppressed
Buspirone Hcl	Buspirone Hcl	17	suppressed
Nitroglycerin	Nitroglycerin	17	13
Olmesartan Medoxomil	Olmesartan Medoxomil	17	suppressed
Trulicity	Dulaglutide	17	suppressed
Azelastine Hcl	Azelastine Hcl	16	suppressed
Breo Ellipta	Fluticasone/Vilanterol	16	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	15	suppressed
Probenecid	Probenecid	15	suppressed
Ramipril	Ramipril	15	suppressed
Tizanidine Hcl	Tizanidine Hcl	15	suppressed
Clonidine Hcl	Clonidine Hcl	14	suppressed
Glipizide	Glipizide	14	suppressed
Jardiance	Empagliflozin	14	suppressed
Myrbetriq	Mirabegron	14	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	14	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	12	suppressed
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	12	suppressed
Lansoprazole	Lansoprazole	12	suppressed
Naproxen	Naproxen	12	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	12	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	11	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	11	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	11	suppressed
Temazepam	Temazepam	11	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error